Goldman Sachs
ARRY

Goldman Sachs’s Array Biopharma Inc ARRY Stock Holding History

Goldman Sachs’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-290,000
Closed -$3.57M – 6847
2017
Q3 		$3.57M Buy
+290,000
New +$2.69M ﹤0.01% 3469
2016
Q1 		– Sell
-306,400
Closed -$1.29M – 7449
2015
Q4 		$1.29M Sell
306,400
-161,100
-34% -$735K ﹤0.01% 4047
2015
Q3 		$2.13M Sell
467,500
-107,500
-19% -$637K ﹤0.01% 3722
2015
Q2 		$4.15M Sell
575,000
-415,800
-42% -$3.07M ﹤0.01% 3130
2015
Q1 		$7.3M Buy
990,800
+910,800
+1,139% +$6.48M ﹤0.01% 2551
2014
Q4 		$378K Buy
80,000
+600
+0.8% +$2.37K ﹤0.01% 5552
2014
Q3 		$283K Sell
79,400
-600
-0.8% -$2.37K ﹤0.01% 5811
2014
Q2 		$365K Buy
+80,000
New +$331K ﹤0.01% 5605
2013
Q3 		– Sell
-80,000
Closed -$363K – 6778
2013
Q2 		$363K Buy
+80,000
New +$430K ﹤0.01% 5196

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Goldman Sachs's ARRY Position: Q3 2019 in Review

Goldman Sachs sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 4,025,690 shares — an estimated $187M sold.

Goldman Sachs first reported a position in ARRY in Q2 2013 and held it in 25 quarters. The position peaked at $187M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Goldman Sachs reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Goldman Sachs sold 4,025,690 Array Biopharma Inc shares in Q3 2019, an estimated $187M.
  • Goldman Sachs first reported a position in Array Biopharma Inc in Q2 2013 and held it in 25 quarters.
  • Goldman Sachs's Array Biopharma Inc position peaked at $187M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.